Article Details

VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright

Retrieved on: 2022-06-19 16:22:01

Tags for this article:

Click the tags to see associated articles and topics

VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright. View article details on hiswai:

Excerpt

Two Sigma Investments LP now owns 81,287 shares of the company's stock valued at $113,000 after purchasing an additional 34,262 shares during the last ...

Article found on: www.defenseworld.net

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up